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Abstract
Isocitrate dehydrogenases (IDHs) catalyse oxidative decarboxylation of isocitrate to a-ketoglutarate (a-KG). IDH1 functions in
the cytosol and peroxisomes, whereas IDH2 and IDH3 are both localized in the mitochondria. Heterozygous somatic
mutations in IDH1 occur at codon 132 in 70% of grade II–III gliomas and secondary glioblastomas (GBMs), and in 5% of
primary GBMs. Mutations in IDH2 at codon 172 are present in grade II–III gliomas at a low frequency. IDH1 and IDH2
mutations cause both loss of normal enzyme function and gain-of-function, causing reduction of a-KG to D-2-
hydroxyglutarate (D-2HG) which accumulates. Excess hydroxyglutarate (2HG) can also be caused by germline mutations in
D- and L-2-hydroxyglutarate dehydrogenases (D2HGDH and L2HGDH). If loss of IDH function is critical for tumourigenesis,
we might expect some tumours to acquire somatic IDH3 mutations. Alternatively, if 2HG accumulation is critical, some
tumours might acquire somatic D2HGDH or L2HGDH mutations. We therefore screened 47 glioblastoma samples looking for
changes in these genes. Although IDH1 R132H was identified in 12% of samples, no mutations were identified in any of the
other genes. This suggests that mutations in IDH3, D2HGDH and L2HGDH do not occur at an appreciable frequency in GBM.
One explanation is simply that mono-allelic IDH1 and IDH2 mutations occur more frequently by chance than the bi-allelic
mutations expected at IDH3, D2HGDH and L2HGDH. Alternatively, both loss of IDH function and 2HG accumulation might be
required for tumourigenesis, and only IDH1 and IDH2 mutations have these dual effects.
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Introduction
Gliomas are the most common primary brain tumour,
accounting for 70% of all primary central nervous system
neoplasms. They show wide diversity with respect to location,
morphology, genetic status and response to therapy.
Grade I gliomas occur more in children than in adults, are
generally curable with complete surgical resection and rarely
evolve into higher-grade lesions. WHO grade II or III gliomas are
invasive, progress to higher-grade lesions and have a poor
outcome. Glioblastoma (GBM), the most common and most
malignant glioma, has a very poor prognosis and may develop
rapidly without evidence of a less malignant precursor lesion
(primary glioblastoma), or less commonly through progression
from a lower grade tumour (secondary glioblastoma) [1,2].
Isocitrate dehydrogenases (IDHs) catalyse the oxidative decar-
boxylation of isocitrate to a-ketoglutarate (a-KG) and reduce
NAD
+ or NADP
+ to NADH or NADPH. IDH1 and IDH2 are
homodimeric, NADP
+-dependent enzymes that share consider-
able sequence similarity and an almost identical protein structure
[3]. IDH3 is a heterotetramer composed of two a, one b and one c
subunit. IDH3 is a NAD
+-dependent enzyme. IDH1 is localised to
the cytoplasm and peroxisomes, it is highly expressed in the liver
and to a lesser level in other tissues [4]. As well as being involved in
catalysing the conversion of isocitrate to a-KG, IDH1 is thought to
play a role in cellular metabolic processes such as lipid and glucose
metabolism [5,6], and has been shown to be involved in cellular
defence against reactive oxygen species and radiation [7,8,9].
IDH2 is localised to the mitochondria, is highly expressed in
heart, muscle, activated lymphocytes and moderately in other
tissues [4]. IDH2 plays a key role in the regulation of the
tricarboxylic acid cycle (TCA) and like IDH1, has been shown to
have a protective role against insults such as oxidative stress
[9,10,11].
IDH3 is also localised to the mitochondria and plays a central
role in the TCA cycle.
In 2008, a genome-wide sequencing study identified somatic
mutations in IDH1 in 18 (12%) of 149 patients with GBM [12] and
it was subsequently found that GBMs without IDH1 mutations
often have mutations affecting IDH2 [13]. Both IDH1 and IDH2
mutations are more frequent in grade II-III gliomas and secondary
glioblastoma (70–75%) than in primary glioblastoma (5%) [14],
are present at higher frequencies in younger patients, and are
associated with a relatively favourable prognosis [13,15]. IDH1
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Mutations in IDH1 almost always affect R132, which is the
binding site for isocitrate [12]. Mutations in IDH2 exclusively
affect R172 and R140; the former of these arginines is analogous
to IDH1 R132 [13] [16].
Initial investigations demonstrated that mutated IDH1 had a
reduced affinity for isocitrate [17]. Furthermore, expression of
mutant IDH1 in cultured cells has been shown to reduce the
formation of the enzyme products, a-KG and NADPH [13,17,18].
These structural and biochemical findings suggested that IDH
mutation results in loss of function, the most plausible mechanism
being a dominant negative effect through the formation of
catalytically inactive heterodimers of mutant and wild type
proteins [17]. Deficiency of a-KG might lead to defective function
of a-KG-dependent enzymes such as HIF prolyl hydroxylases.
Subsequent evidence has emerged suggesting that mutant IDH1
and IDH2 are not simply inactive enzymes, but instead possess
novel enzymatic activity [16,19,20]. Dang et al. demonstrated that
mutant, but not wild type, IDH1 catalyses the reduction of a-KG
to D-2HG while converting NADPH to NADP
+. D-2HG
accumulates in glioblastoma cells with IDH1 R132H mutations
[19]. The role of 2HG in tumourigenesis is unclear, although it
may act as an oncometabolite, perhaps competitively inhibiting
a-KG-dependent enzymes [21] [22]. One of the rationales for a
role of 2HG in tumour formation is derived from the observation
of patients suffering from hereditary 2-hydroxyglutaric aciduria.
This is a rare inherited metabolic disorder, caused by homozygous
inactivating germline 2-hydroxyglutarate dehydrogenase (2HGDH)
mutations, that is weakly associated with brain tumours.
If IDH loss-of-function alone is critical for tumourigenesis, we
might expect IDH3 mutations to occur in brain tumours, including
those sub-types with relatively low frequencies of IDH1 and IDH2
mutations. Alternatively, if accumulation of 2HG alone is critical, we
m i g h te x p e c tm u t a t i o n si nD2HGDH and/or L2HGDH.Af u r t h e r ,
morespeculative line of reasoning is that, if patients with mutations in
IDH1 and IDH2 have normal D2HGDH and L2HGDH function,
excess 2HG should simply be converted back to a-KG by 2HGDH.
The failure of this to occur might be due to saturation of the 2HGDH
enzymes, but raises the possibility that patients with IDH1 and IDH2
mutations might also require inactivating mutations in D2HGDH and
L2HGDH for 2HG to accumulate.
We therefore analysed a set of GBM for mutations in IDH1,
IDH2, IDH3, D2HGDH and L2HGDH.
Results and Discussion
We studied 47 glioblastomas (WHO grade IV). Heterozygous
mutations of IDH1 were found in 6/47 tumours (12%). All 6
mutations were single base substitutions c.395G.A occurring at
residue R132, resulting in an arginine to histidine (p.R132H)
substitution (Figure 1). This frequency is consistent with previously
described data. No mutations were found in IDH2, in keeping with
the lower frequency of such changes than mutations in IDH1.W e
sequenced all the exons of IDH3A, IDH3B and IDH3G, which
encode the a, b, and c subunits of the IDH3 heterotetramer, and
all the exons of D2HGDH and L2HGDH. In all cases examined we
did not find any mutations. Known SNPs were found within each
gene (details not shown).
Figure 1. Identification of the G395A mutation at codon 132 by sequence analysis of the IDH1 gene. The electropherogram shows a
representative example of the heterozygous, single base G-to-A substitution at nucleotide position 395 of the IDH1 gene (right panel) and the
corresponding wild-type sequence (left panel). The mutation was detected in 6 out of 47 glioblastomas analyzed.
doi:10.1371/journal.pone.0019868.g001
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inactivated by other mechanisms such as promoter methylation or
miRNA over-expression. We therefore evaluated the expression of
thecorrespondingproteinsinhumanglioblastomassamples(Figure2).
D2HGDH and L2HGDH were detected in GBMs carrying wild type
IDH1 and IDH2 genes, as well as in IDH1-mutants tumours. It is
highly unlikely that the loss of D2HGDH or L2HGDH expression
plays an important role in the pathogenesis of human GBMs.
Mutations in IDH3, D2HGDH and L2HGDH (or loss of
expression of the 2HGDHs) do not therefore occur at an
appreciable frequency in GBM. One explanation is simply that
mono-allelic IDH1 and IDH2 mutations occur more frequently by
chance than the bi-allelic mutations expected at IDH3, D2HGDH
and L2HGDH. Alternatively, both loss of IDH function and 2HG
accumulation are required for tumourigenesis, and only IDH1 and
IDH2 mutations have these dual effects. It is also possible that
2HG accumulation is an epiphenomenon and that IDH3 loss-of-
function does not lead to sufficient deficiency of a-KG to promote
tumourigenesis. There might also be an unknown mechanism of
tumourigenesis that is specific to defects in IDH1 or IDH2.
Moreover our data suggest that in patients with mutations of
IDH1 and IDH2 and normal D2HGDH and L2HGDH function,
the excess 2HG is not converted back to a-KG by 2HGDH,
perhaps due to the saturation of the latter enzyme. A recent report
identified heterozygous germline IDH2 mutations in patients with
idiopathic D-2-hydroxyglutaric aciduria, carrying no mutations in
D2HGDH and consistently increased D-2HG levels in body fluids
[23]; interestingly, the patient did not develop brain tumours.
The mechanisms by which IDH1 and IDH2 mutations cause
tumourigenesis remain largely unclear, as do the putative
alternative functional deficiencies in IDH-wildtype gliomas.
However, even if 2HG has no direct pathogenic role it has
potential as a specific marker of IDH1 or IDH2 mutations, to
diagnose or monitor IDH-mutant glioma [24].
Materials and Methods
Sample collection
All brain tumours were obtained from the neuropathology
department at The Royal Free Hospital, Hampstead, London. All
47 samples analysed were confirmed to be WHO grade IV
glioblastoma. We have worked solely on anonymously samples.
Study of these has been approved by Oxfordshire REC B 05/
Q1605/66.
Figure 2. D2HGDH and L2HGDH are expressed in wildtype IDH1/2 and IDH1 R132H glioblastomas. Expression of D2HGDH and L2HGDH
in normal brain is shown respectively in panels A and B. D2HGDH and L2HGDH were detected in brain tumour samples carrying either wild-type
IDH1/IDH2 (C and D) or mutated IDH1 allele (E and F) by immunohistochemistry. Scale bar represents 50 mm in all panels.
doi:10.1371/journal.pone.0019868.g002
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DNA was extracted from paraffin embedded samples using
DNeasy Blood and Tissue from Quiagen
R (Alameda, CA),
following the manufacturer’s instructions.
Sequencing analysis
Mutation screening of each gene was performed by direct
sequencing of genomic DNA in forward and reverse orientations
using the Applied Biosystems BigDye terminator reaction kit and
the AB 3730xl sequencing machine (Applied Biosystems, Foster
City, CA). Primer sequences were designed to encompass the
coding region and splice sites of exon 4 of IDH1 and IDH2, and all
exons of IDH3A (RefSeq: NM_005530.2), IDH3B (RefSeq:
NM_174855.1), IDH3G (RefSeq: NM_004135.2 for the transcript
variant 1 and RefSeq: NM_174869.1 for the transcript variant 2),
L2HGH (RefSeq: NM_024884.2) and D2HGDH (RefSeq:
NM_024884.2). Primer sequences and PCR conditions are
available on request.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (4 mm) were
de-waxed in xylene and rehydrated through graded alcohols to
water. Endogenous peroxidase was blocked using 1.6% H2O2 for
20 minutes. For antigen retrieval, sections were pressure cooked in
10 mmol/L citrate buffer (pH6.0) for 5 minutes. Sections were
blocked with 10% serum for 30 minutes. Slides were incubated
with primary polyclonal antibodies anti human D2HGDH
(ProteinTech Group, Chicago, IL 60612, 1:50), or anti human
L2HGDH (ProteinTech Group, Chicago, IL 60612, 1:100) for
1 hour. Goat anti-rabbit secondary antibody was applied for one
hour at room temperature. Sections were then incubated in ABC
(Vector labs) for 30 minutes. DAB solution was applied for 2–5
minutes and development of the colour reaction was monitored
microscopically. Slides were counterstained with haematoxylin,
dehydrated, cleared and then mounted. Images were taken at 206
magnification.
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